Dario earned a Ph.D. in Organic Chemistry from the Facultad de Ciencias Exactas y Naturales, UBA, Argentina. He conducted postdoctoral studies with Sir Derek Barton at Texas A&M University. His industrial career includes Rohm & Haas, Schering-Plough Research Institute, 3-Dimensional Pharmaceuticals, Gliatech, Neurogen, Lundbeck, CoNCERT, Sage and Sunovion Pharmaceuticals, where he is currently Director, Medicinal Chemistry. He contributed to the discovery of the marketed PAR-1 antagonist vorapaxar and the clinical compounds NGD-4715, Lu AF09535, and CTP-692. Dario coauthored over 100 articles, patents or patent applications, and book chapters, and edited the book Allosterism in Drug Discovery. Current interests include molecular concepts at the chemistry/biology interface to enhance the translatability of preclinical research.
Khusru Asadullah, MD, is Professor of Medicine at the department of Dermatology, Charité – Berlin Medical School, Chairman of the Management Board of German Skin Research Center, board certified consultant for Dermatology, Venerology, Allergology and Immunology, former Vice-President Target Discovery at Bayer-Schering Pharma.
Asadullah K, Busch A, Gottwald M, Reinke P, Landeck L (2015) Industry-academia collaborations for biomarkers. Nat Rev Drug Discov 14 (12): 805-6.
Prinz F, Schlange T, Asadullah K (2011) Believe it or not: how much can we rely on published data on potential drug targets? Nat Rev Drug Discov 10 (9): 712.
Ulrich Dirnagl, MD, PhD, is the Director of the Department of Experimental Neurology at the Charité Universitätsmedizin Berlin, Chief Executive Director of the Center for Stroke Research Berlin, Clinical program coordinator of the Excellence Cluster NeuroCure and the Berlin partner site of the German Center for Neurodegenerative Diseases (DZNE), as well as Program Director of the International Graduate Program Medical Neuroscience. Prof. Dirnagl studied medicine at Ludwig Maximilians University in Munich, where he also obtained a PhD in Neuroscience. The research of Ulrich Dirnagl is focused on stroke, cerebral blood flow regulation, and brain imaging. To improve the predictiveness of preclinical translational research, he is actively promoting the introduction of quality standards for experimental design and reporting, as well as international collaboration in large, phase III-type preclinical trials.
Visit Prof Dirnagl’s blog at https://dirnagl.com.
Dirnagl U, Przesdzing I (2016) A pocket guide to electronic laboratory notebooks in the academic life sciences. F1000 Res 5:2.
Holman C, Piper SK, Grittner U, Diamantaras AA, Kimmelman J, Siegerink B, Dirnagl U (2016) Where have all the rodents Gone? The effects of attrition in experimental research on cancer and stroke. PLoS Biol 14(1):e1002331.
Begley CG, Buchan AM, Dirnagl U (2015) Robust research: Institutions must do their part for reproducibility. Nature 525: 25-7.